2020 OCT 06 Pres Trumps WH. Dr’s Update Public & Trump Returns to WH, Addresses Nation

Molar mass: 392.464 g/mol
Formula: C22H29FO5
CAS ID: 50-02-2
ChemSpider ID: 5541
ChEMBL Id: 384467
IUPHAR ID: 2768

Dexamethasone is a type of corticosteroid medication. It is used in the treatment of many conditions, including rheumatic problems, a number of skin diseases, severe allergies, asthma, chronic obstructive lung disease, croup, brain swelling, eye pain following eye surgery, and along with antibiotics in tuberculosis. Wikipedia

Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report

Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report

July 17, 2020 | DOI: 10.1056/NEJMoa2021436

June 2020 | DOI: 10.1101/2020.06.22.20137273

CONCLUSIONS
In patients hospitalized with Covid-19, the use of dexamethasone resulted in lower 28-day mortality among those who were receiving either invasive mechanical ventilation or oxygen alone at randomization but not among those receiving no respiratory support. (Funded by the Medical Research Council and National Institute for Health Research and others; RECOVERY ClinicalTrials.gov number, NCT04381936. opens in new tab; ISRCTN number, 50189673. opens in new tab.)

x

Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Additional Benefit

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial^[1]https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31022-9/fulltext

Published: 2020 MAY 26

Published: 2020 APR 29

DOI: 10.1208/s12248-020-00459-8

DOI: 10.1016/S0140-6736(20)31022-9

PMCID: PMC7250281 | PMID: 32458279

Abstract (PMC7250281)

Remdesivir is one of the most promising drugs to treat COVID-19 based on the following facts: remdesivir has a broad-spectrum antiviral mechanism of action; it demonstrated in vitro activity against SARS-CoV-2 and in vivo efficacy in animal models against the similar coronavirus MERS-CoV; its safety profile has been tested in Ebola patients and in compassionate use in COVID-19 patients.

Currently, remdesivir is being investigated in ten randomized controlled trials against COVID-19.

The dose regimen of remdesivir is an IV loading dose of 200 mg on day 1 followed by daily IV maintenance doses of 100 mg for 5–9 days. Based on our data analysis, however, remdesivir with IV administration alone is unlikely to achieve excellent clinical efficacy.

.

This analysis is based on the following observations: plasma exposures of remdesivir and its active metabolite are unlikely to be correlated with its clinical efficacy; remdesivir and its active metabolites are unlikely to be adequate in the lung to kill the SARS-CoV-2 virus.

Even if remdesivir demonstrates benefits in the current randomized controlled trials, its efficacy may be limited.

We suggest that a combination of an IV and pulmonary delivery dose regimen should be studied immediately to realize a potentially more effective antiviral therapy against COVID-19.

Content 01:
Raw Cut: Yes 
Reporter Commentary: Yes 
Edited by 4cm: Yes 

Content 02:
Raw Cut: No  
Reporter Commentary: No 
Edited by 4cm: Yes 

Content 03:
Raw Cut: No 
Reporter Commentary: No 
Edited by 4cm: Yes 

.

.
.
Situation Vacant